The value of pre operative S-100B and SUV in clinically stage III melanoma patients undergoing therapeutic lymph node dissection

European Journal of Surgical Oncology

Volumn 37, Issue 3, 2011, Pages 225-232

  Kruijff, S ^a   Bastiaannet, E ^a   Speijers, M J ^a   Kobold, A C M ^a   Brouwers, A H ^a   Hoekstra, H J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Melanoma; S 100B; Survival; SUV; TLND

Indexed keywords

FLUORODEOXYGLUCOSE; PROTEIN S100B;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; DISEASE FREE SURVIVAL; DRUG UPTAKE; FEMALE; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SPIRAL COMPUTER ASSISTED TOMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; NERVE GROWTH FACTORS; POSITRON-EMISSION TOMOGRAPHY; PROPORTIONAL HAZARDS MODELS; RADIOPHARMACEUTICALS; S100 PROTEINS; SKIN NEOPLASMS; TOMOGRAPHY, SPIRAL COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 79851513015     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2010.12.013     Document Type: Article

References (30)

1. D. Rinne, R.P. Baum, G. Hor, and R. Kaufman Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients Cancer 85 1999 1199 1201 (Pubitemid 29115602)
2. http://www.ikcnet.nl/page.php?id=2755&;nav-id=97.
3. E. De Vries, L.V. van de Poll-Franse, W.J. Louwmann, F.R. de Gruijl, and J.W. Coebergh Predictions of skin cancer incidence in the Netherlands up to 2015 Br J Dermatol 152 2005 481 488 (Pubitemid 40547122)
4. C.M. Balch, J.E. Gershenwald, and S.J. Soong Final version of 2009 AJCC melanoma staging and classification J Clin Oncol 27 2009 6199 6206
5. E. Bastiaannet, T. Wobbes, and O.S. Hoekstra Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomographyin patients with melanoma with palpable lymph node metastases: diagnosticaccuracy and impact on treatment J Clin Oncol 27 2009 4774 4780
6. C.M. Balch, J.E. Gershenwald, and S. Soong Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases J Clin Oncol 28 2010 2452 2459
7. B.R. Hill, and C. Levi Elevation of a serum component in neoplastic disease Cancer Res 14 1954 513 515
8. H. Cogas, A.M.M. Eggermont, and A. Hauschild Biomarkers in melanoma Ann Oncol 20 2009 8 13
9. G. Krahn, P. Kaskel, and S. Sander S100 beta is a more reliable tumor marker in peripheral for patients with newly occurred melanoma mestases compared with MIA, albumine and lactaat-dehydrogenase Anticancer Res 21 2001 1311 1316 (Pubitemid 32494139)
10. L.H. Smit, C.M. Korse, and A.A. Hart Normal values of S-100B predict prolonged survival for stage IV melanoma patients Eur J Cancer 41 2005 386 392 (Pubitemid 40187209)
11. S. Kruijff, E. Bastiaannet, and A.C. Muller-Kobold S-100B concentrations predict disease-free survival in stage III melanoma patients Ann Surg Oncol 16 2009 3455 3462
12. A.A. Tarhini, J. Stuckert, S. Lee, C. Sander, and J.M. Kirkwood Prognostic significance of serum S-100B surgically resected melanoma patients participating in Intergroup Trial ECOG 1694 J Clin Oncol 1 27 2008 38 44
13. G. Ghanem, B. Loir, and R. Morandini On the release and half-life of S100B protein in the peripheral blood of melanoma patients Int J Cancer 94 2001 586 590
14. E. Mochiki, H. Kuwano, H. Katoh, T. Asao, N. Oriuchi, and K. Endo Evaluation of 18F-2-eoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer World J Surg 28 2004 247 253 (Pubitemid 38375523)
15. E. Bastiaannet, O.S. Hoekstra, W.J. Oyen, P.L. Jager, T. Wobbes, and H.J. Hoekstra Level of fluorodeoxyglucose uptake predicts risk for recurrence in melanoma patients presenting with lymph node metastases Ann Surg Oncol 13 2006 919 926
16. E. Bastiaannet, J.C. Beukema, and H.J. Hoekstra Radiation therapy following lymph node dissection in melanoma patients: treatment, outcome and complications Cancer Treat Rev 31 2005 18 26 (Pubitemid 40246987)
17. M.A. Henderson, B. Burmeister, and J.F. Thompson Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: results of an intergroup randomized trial. 2009 ASCO Annual meeting J Clin Oncol 27 2009 Supplement:Abstract No.LBA9084
18. K. Hamacher, H.H. Coenen, and G. Stocklin Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution J Nucl Med 27 1986 235 238 (Pubitemid 17024868)
19. M. Westerterp, J. Pruim, and W. Oyen Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters Eur J Nucl Med Mol Imaging 34 2007 392 404 (Pubitemid 46295349)
20. S.J. Soong, S. Ding, and D. Coit Predicting survival outcome of localized melanoma: an electronic prediction tool based on the AJCC melanoma database Ann Surg Oncol 17 2010 2006 2014 www.melanomaprognosis.org
21. J. Klode, J. Dissmond, S. Grabbe, U. Hillen, T. Poeppel, and C. Boeing Sentinel lymph node excision and PET-CT in the initial stage of malignant melanoma: a retrospective analysis of 61 patients with malignant melanoma in American Joint Committee on cancer stages I and II Dermatol Surg 36 2010 439 445
22. D.L. Morton, J.F. Thompson, and A.J. Cochran Sentinel-node biopsy or nodal observation in melanoma N Engl J Med 355 2006 1307 1317 (Pubitemid 44465459)
23. D.L. Morton, J.F. Thompson, and A.J. Cochran Sentinel node biopsy and immediate lymphadenectomy for occult metastases versus nodal observation and delayed lymphadenectomy for nodal recurrence Ann Surg Oncol 1 17 Suppl. 2010 S22 S23 (Abstract 53)
24. G.S. Mijnhout, O.S. Hoekstra, M.W. van Tulder, G.J. Teule, and W.L. Deville Systematic review of the diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography in melanoma patients Cancer 91 2001 1530 1542 (Pubitemid 32319265)
25. T.S. Aukema, R.A. Valdés Olmos, and M.W. Wouters Utility of preoperative 18F-FDG PET/CT and brain MRI in melanoma patients with palpable lymph node metastases Ann Surg Oncol 17 2010 2773 2778
26. A.P. Hamberg, C.M. Korse, J.M. Bonfrer, and G.C. de Gast Serum S-100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma Melanoma Res 13 2003 45 49 (Pubitemid 36269813)
27. H. Minn, A.C. Clavo, R. Grenman, and R.L. Wahl In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamouscell carcinoma of the head and neck J Nucl Med 36 1995 252 258
28. C. Sperti, C. Pasquali, F. Chierichetti, A. Ferronato, G. Decet, and S. Pedrazzoli 18 Fluorodeoxyglucose positron emission tomography in predicting survival of patients with pancreatic carcinoma J Gastrointest Surg 7 2003 953 959
29. Y. Sugawara, K.R. Zasadny, A.W. Neuhoff, and R.L. Wahl Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction Radiology 213 1999 521 525 (Pubitemid 29510601)
30. R. Boellaard, N.C. Krak, O.S. Hoekstra, and A.A. Lammertsma Effects of noise, image resolution and ROI definition on the accuracy of standard uptake values: a simulation study J Nucl Med 45 2004 1519 1527 (Pubitemid 47618506)